Revenue growth of 5%Continuous strong growth in theranostics sales: +27%Theranostics revenues up to 50% of total salesCroissy-Beaubourg and Montpellier, April 27, 2017, 8:00am CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME plans), a company…
Croissy-Beaubourg and Montpellier, March 28, 2017, 8am CEST – Theradiag (ISIN: FR0004197747, ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, is today announcing further progress in bringing its LISA TRACKER® monitoring tests…
Very strong revenue growth of 19% Ramp-up in Theranostics to €4 million or 45% of total revenuesSignificant reduction in the operating lossStrengthening of the cash position: €3.7 million Croissy-Beaubourg and Montpellier, March 1, 2017, 5:45pm (CET) – THERADIAG…